title: MicroRNA-383 is a tumor suppressor and potential prognostic biomarker in human non-small cell lung caner.
abstract: OBJECTIVE
  The purpose of this study is to examine the expression and clinical significance microRNA-383 (miR-383) in non-small cell lung cancer (NSCLC) both in vitro and in vivo.
  
  
  METHODS
  Tumorous miR-383 expressions were compared between NSCLC cell lines and normal lung cells. MiR-383 was upregulated in A549 and H596 cells to evaluate its tumor suppressive effect on NSCLC proliferation, invasion and migration in vitro. MiR-383 expression was also compared between 139-paired clinical NSCLC tissues and their adjacent non-carcinoma lung tissues, as well as between early-stage NSCLC tissues and advanced-stage NSCLC tissues. Correlation between tumorous miR-383 expression and NSCLC patients' clinicopathological features and overall survival (OS) were also statistically analyzed.
  
  
  RESULTS
  MiR-383 was significantly downregulated in NSCLC cell lines. MiR-383 overexpression reduced proliferation, invasion and migration of A549 and H596 cells. In clinical samples, miR-383 was also found to be markedly downregulated in NSCLC carcinomas than in non-carcinoma lung tissues, and in advanced-stage carcinomas than in early-stage carcinomas. It was also found low tumorous miR-383 expression was significantly associated with NSCLC patients' poor prognosis, including advanced TNM stages, positive lymph node metastasis, and shorter OS.
  
  
  CONCLUSIONS
  Endogenous miR-383 is a functional tumor suppressor in NSCLC. It may also serve as an independent prognostic factor for patients with NSCLC.
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Yanhong
authors.initials: Y
authors.lastname: Shang
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Aimin
authors.initials: A
authors.lastname: Zang
authors.affiliation: Department of General Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, China. Electronic address: zch7881@aol.com.
authors.forename: Jinghua
authors.initials: J
authors.lastname: Li
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Youchao
authors.initials: Y
authors.lastname: Jia
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Xiaofang
authors.initials: X
authors.lastname: Li
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Ran
authors.initials: R
authors.lastname: Huo
authors.affiliation: Department of General Surgery, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Jihong
authors.initials: J
authors.lastname: Yang
authors.affiliation: Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Jia
authors.initials: J
authors.lastname: Feng
authors.affiliation: Department of Science and Research, Affiliated Hospital of Hebei University, Baoding, 071000, China.
authors.forename: Kun
authors.initials: K
authors.lastname: Ge
authors.affiliation: Department of Pathology, Health Science Center, Hebei University, Baoding, 071000, China.
authors.forename: Yongbin
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, The First Hospital of ShiJiazhuang, ShiJiazhuang, 050010, China.
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhang
authors.affiliation: Department of Clinical Epidemiology, The First Hospital of Jilin University, Changchun, 130021, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Jiang
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000235:genetics; D015536:Down-Regulation / Q000235:genetics; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics* / Q000473:pathology; D008297:Male; D035683:MicroRNAs / Q000235:genetics* / Q000378:metabolism; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D011379:Prognosis; D016019:Survival Analysis
chemical_list: D014408:Biomarkers, Tumor; C558685:MIRN383 microRNA, human; D035683:MicroRNAs
keywords: Cancer migration; Cancer proliferation; MiR-383; NSCLC; Overall survival